http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김성진,김민회,서민철,Yeon-Gon Mo,Seung Wook Chang,이신두 한국정보디스플레이학회 2011 Journal of information display Vol.12 No.4
Herein, the integration of solution-processed polymer thin-film transistors (TFTs) that were fabricated using selective wettability through ultraviolet (UV) exposure into a reflective liquid crystal display is demonstrated. From the experimental results of energy-dispersive spectroscopy, the composition of carbon and fluorine enhancing the hydrophobicity in the polymer chains was found to play a critical role in the wetting selectivity upon UV exposure. The polymer TFTs fabricated through the wettability-patterning process exhibited long-term stability and reliability. This wetting-selectivity-based patterning technique will be useful for constructing different types of solution-processed electronic and optoelectronic devices.
Chang-Keun Cho,Ju Yeon Mo,Eunvin Ko,Pureum Kang,Choon-Gon Jang,Seok-Yong Lee,Yun Jeong Lee,Jung-Woo Bae,Chang-Ik Choi 대한약학회 2024 Archives of Pharmacal Research Vol.47 No.2
Pitavastatin, a potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is indicated for the treatment of hypercholesterolemiaand mixed dyslipidemia. Hepatic uptake of pitavastatin is predominantly occupied by the organic anion transportingpolypeptide 1B1 (OATP1B1) and solute carrier organic anion transporter family member 1B1 ( SLCO1B1 ) gene, which isa polymorphic gene that encodes OATP1B1. SLCO1B1 genetic polymorphism signifi cantly alters the pharmacokinetics ofpitavastatin. This study aimed to establish the physiologically based pharmacokinetic (PBPK) model to predict pitavastatinpharmacokinetics according to SLCO1B1 genetic polymorphism. PK-Sim ® version 10.0 was used to establish the wholebodyPBPK model of pitavastatin. Our pharmacogenomic data and a total of 27 clinical pharmacokinetic data with diff erentdose administration and demographic properties were used to develop and validate the model, respectively. Physicochemicalproperties and disposition characteristics of pitavastatin were acquired from previously reported data or optimized to capturethe plasma concentration–time profi les in diff erent SLCO1B1 diplotypes. Model evaluation was performed by comparing thepredicted pharmacokinetic parameters and profi les to the observed data. Predicted plasma concentration–time profi les werevisually similar to the observed profi les in the non-genotyped populations and diff erent SLCO1B1 diplotypes. All fold errorvalues for AUC and C max were included in the two fold range of observed values. Thus, the PBPK model of pitavastatin indiff erent SLCO1B1 diplotypes was properly established. The present study can be useful to individualize the dose administrationstrategy of pitavastatin in individuals with various ages, races, and SLCO1B1 diplotypes.
Molecular Epidemiology of Viral Conjunctivitis in the Southern Region of South Korea, 2012-2016
Duck Woong Park,Min Ji Kim,Kwang gon Kim,Sun Ju Cho,Hye Jung Park,Ji Hyun Shin,Yi Deun Ha,Mi Hee Seo,Jang Hoon Kim,Yeon Lee,Myoung Doo Park,Hi-Mo Yoon,Eun Sun Kim,Young Jin Hong,Hyeyoung Kee,Jae Keun 대한미생물학회 2018 Journal of Bacteriology and Virology Vol.48 No.2